ΔNp73β puts the brakes on DNA repair

Genes and Development

Volumn 24, Issue 6, 2010, Pages 517-520

  Vernersson Lindahl, Emma ^a   Mills, Alea A ^a  

^a Cold Spring Harbor Laboratory ^*  (United States)

Author keywords

Apoptosis; DNA damage response; Neurodegeneration; P53; P73

Indexed keywords

ATM PROTEIN; BINDING PROTEIN; PROTEIN DELTA NP73; PROTEIN MDM2; PROTEIN P53; PROTEIN P53 BINDING PROTEIN 1; PROTEIN P73; UNCLASSIFIED DRUG;

APOPTOSIS; CELL AGING; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; NEGATIVE FEEDBACK; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN INDUCTION; PROTEIN MODIFICATION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL AGING; DISEASE MODELS, ANIMAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 77949385912     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1914210     Document Type: Short Survey

References (37)

1. Buhlmann S, Putzer BM. 2008. DNp73 a matter of cancer: Mechanisms and clinical implications. Biochim Biophys Acta 1785: 207-216.
2. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. 2002. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251.
3. Collado M, Serrano M. 2006. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6: 472-476.
4. Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, Iwabuchi K, Doherty AJ. 2002. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J 21: 3863-3872.
5. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. 2006. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 66: 9362-9368.
6. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
7. Emmrich S, Wang W, John K, Li W, Putzer BM. 2009. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer 8: 61. doi: 1186/1476-4598-8-61.
8. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564.
9. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. 2005. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
10. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, Vogel H, Mills AA. 2009. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11: 1451-1457.
11. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. 1994. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci 91: 6098-6102.
12. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
13. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M. 2002. p53 induces the expression of its antagonist p73 ΔN, establishing an autoregulatory feedback loop. Oncogene 21: 4715-4727.
14. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, Mills AA. 2005. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes & Dev 19: 1986-1999.
15. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM, Roop DR, Bradley A, Mills AA. 2006. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci 103: 8435-8440.
16. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. 2006. Expression of ΔNp73 and TAp73α independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 12: 3922-3927.
17. Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M, Bonati A. 2009. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res 15: 6495-6502.
18. Meek DW. 2009. Tumour suppression by p53: A role for the DNA damage response? Nat Rev Cancer 9: 714-723.
19. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
20. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
21. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
22. Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Hayashi S, Hosoda M, Todo S, Nakagawara A. 2003. Negative autoregulation of p73 and p53 by ΔNp73 in regulating differentiation and survival of human neuroblastoma cells. Cancer Lett 197: 105-109.
23. Perez-Losada J, Wu D, DelRosario R, Balmain A, Mao JH. 2005. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene 24: 5521-5524.
24. Petrenko O, Zaika A, Moll UM. 2003. ΔNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 23: 5540-5555.
25. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289: 304-306.
26. Rinne T, Brunner HG, van Bokhoven H. 2007. p63-associated disorders. Cell Cycle 6: 262-268.
27. Senoo M, Manis JP, Alt FW, McKeon F. 2004. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 6: 85-89.
28. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z, Elvin JA, Bronson RT, Crum CP, McKeon F. 2006. p63 protects the female germ line during meiotic arrest. Nature 444: 624-628.
29. Tannapfel A, John K, Mise N, Schmidt A, Buhlmann S, Ibrahim SM, Putzer BM. 2008. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 29: 211-218.
30. Tissir F, Ravni A, Achouri Y, Riethmacher D, Meyer G, Goffinet AM. 2009. ΔNp73 regulates neuronal survival in vivo. Proc Natl Acad Sci 106: 16871-16876.
31. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, et al. 2008. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes & Dev 22: 2677-2691.
32. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K. 2004. Expression of ΔNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911.
33. Ward IM, Minn K, van Deursen J, Chen J. 2003. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol 23: 2556-2563.
34. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A,Wakeham A, Arsenian-Henriksson M, Melino G, et al. 2010. Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway. Genes & Dev (this issue). doi: 10.1101/gad.1873910.
35. Wilson KA, Stern DF. 2008. NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway. Cell Cycle 7: 3584-3594.
36. Yang A, Schweitzer R, Sun D, Kaghad M,Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, et al. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
37. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, et al. 2000. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404: 99-103.